Vical Incorporated (NASDAQ:VICL) announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus (CMV) vaccine, ASP0113, versus placebo in kidney transplant patients receiving an organ from a CMV-seropositive donor. Results from the study demonstrated that the trial did not meet its primary endpoint, which was the proportion of patients having CMV viremia defined as a plasma viral load of ≥ 1000 IU/mL by central laboratory assay through one year after first injection of study drug. Additionally, the secondary endpoints of CMV-associated disease and CMV-specific antiviral therapy, which were evaluated by an independent, blinded Adjudication Committee, were similar in both treatment groups.
The safety profiles were generally similar between treatment groups. However, local injection site reactions were more common in the ASP0113 treatment group. Further detailed data from the trial is expected to be disclosed at an upcoming scientific congress.
“The unmet medical need in addressing CMV infection in transplant patients remains high. Although we had hoped for a different outcome, we look forward to further analyzing these data in hopes of contributing knowledge to the future development programs in this patient population,” said Bernhardt G. Zeiher, M.D., President, Development, Astellas. “In addition, we continue to focus on execution of our Phase 3 study in hematopoietic cell transplant (HCT) recipients and are pleased to announce that we have met our target enrollment.”
“We are pleased with our collaborative relationship with Astellas, and we look forward to the results from the pivotal Phase 3 study in HCT recipients, which we expect to obtain during the fourth quarter of 2017,” said Vijay Samant, President and Chief Executive Officer, Vical. (Original Source)
Shares of Vical are currently trading at $2.86, down $1.00 or -25.91%. VICL has a 1-year high of $5.90 and a 1-year low of $2.81. The stock’s 50-day moving average is $4.06 and its 200-day moving average is $4.10.
On the ratings front, H.C. Wainwright analyst Shaunak Deepak reiterated a Buy rating on VICL, in a report issued on August 10. According to TipRanks.com, Deepak has a yearly average return of -20.4%, a 45.0% success rate, and is ranked #3913 out of 4163 analysts.
Vical, Inc. researches and develops biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its core technology involves the insertion of DNA into plasmids designed to deliver the desired genes into cells in the body. Its development programs include Infectious disease vaccines for use in high-risk populations and Infectious disease vaccines for general pediatric, adolescent and adult populations.